Company Description
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
| Country | United States |
| Founded | 2018 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
Contact Details
Address: 12750 High Bluff Drive Suite 475 San Diego, California 92130 United States | |
| Phone | 858-246-6240 |
| Website | belitebio.com |
Stock Details
| Ticker Symbol | BLTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001889109 |
| CUSIP Number | 07782B104 |
| ISIN Number | US07782B1044 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors and Chief Executive Officer |
| Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer and Director |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2024 | 144 | Filing |
| May 30, 2024 | 144 | Filing |
| May 30, 2024 | 144 | Filing |
| May 17, 2024 | 144 | Filing |
| May 16, 2024 | 144 | Filing |
| May 14, 2024 | 6-K | Report of foreign issuer |
| Apr 29, 2024 | 424B5 | Filing |
| Apr 26, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | 144 | Filing |
| Mar 22, 2024 | 6-K | Report of foreign issuer |